Roquette Ventures invests in Magellan Life Sciences

Roquette Ventures, a French investment company, is investing in Magellan Life Sciences Ltd., a U.K. biotech company that develops plant-inspired proteins through a fermentation process. The seed round was led by Roquette Ventures and completed with investments from U.S.-based SOSV and three European business angels. This partnership aims at accelerating the market entry of new protein sweeteners.

Magellan Life Sciences has developed a proprietary expression and fermentation platform to produce new generations of protein sweeteners. The current funding round will be used for optimization and scaling up of the manufacturing process of the protein sweeteners.

Edouard Nuttin, general manager of Roquette Ventures, said, “In a context of global health challenges such as the rise of sugar-related diseases like diabetes or obesity, Magellan’s protein sweeteners have a tremendous potential to meet the increasing demand of consumers for healthier alternatives to sugar.”

Abhiram Dukkipati, CEO of Magellan, said, “We are thrilled to have Roquette Ventures, SOSV and the angel investors invest in Magellan. With their varied backgrounds, each investor brings significant value to help guide us in our mission.”